^
Association details:
| Biomarker: | BCL2 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | lisaftoclax (APG-2575) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Published date:
09/01/2020
Excerpt:
After treating with increasing concentrations of APG2575 for 24 h, we found the apoptosis rate significantly increased in OCI-LY8 and OCI-LY19 cells in a dose-dependent manner (Fig. 2a). APG-2575 induced rapid apoptosis within 4 h in OCI-LY8 and OCI-LY19 cells with high expression of BCL-2 in a time-dependent manner...
DOI:
10.3727/096504020X15825405463920
